High-sensitivity C-reactive Protein and Regression of Low-grade Squamous Intraepithelial Lesion: The Role of Low-grade Inflammation in Cervical Carcinogenesis

Sangjeong Ahn1,†, Gi Jeong Kim1,†, Sung-Im Do1, Kyungun Kim1, Hyunjoo Lee1, In-Gu Do1, Dong-Hoon Kim1, Seoung Wan Chae1, Seungho Ryu2,3,4, and Jin Hee Sohn1

1Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
2Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
3Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, Seoul, Republic of Korea
4Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea

Received April 14, 2020; accepted August 20, 2020; released online February 2, 2021

ABSTRACT

Background: Inflammation is emerging as a potential mechanism of cervical carcinogenesis. However, few studies have investigated the association between host inflammatory status and the natural course of cervical precursor lesion. The aim of this study was to assess the probability of LSIL regression, associated with an inflammatory biomarker, high-sensitivity C-reactive protein (hs-CRP).

Methods: In a longitudinal cohort study, female participants were examined annually or biannually using cervical cytology between 2006 and 2015. Incident LSIL cases were included in the analysis, with regression defined as at least one consecutive normal cytologic result. A total of 520 women aged 22–64 years were followed up for LSIL regression. The multivariable-adjusted hazard ratios (HRs) for LSIL regression were estimated using a parametric proportional hazards model.

Results: During 827.5 person-years of follow-up, 486 out of 520 subjects (93.5%) showed LSIL regression. After adjusting several important potential confounders, a higher quartile of hs-CRP levels was significantly associated with a lower rate of regression (for quartile 4 vs quartile 1, inverse HR 1.33; 95% CI, 1.04–1.69; P for trend = 0.028).

Conclusions: The low rate of spontaneous regression recorded in women with higher hs-CRP lends support to the role of the perturbed host inflammatory status in cervical carcinogenesis, and suggests that hs-CRP level could help monitor LSIL.

Key words: chronic inflammation; cervix; regression; low-grade squamous intraepithelial lesions; hs-CRP

Copyright © 2021 Sangjeong Ahn et al. This is an open access article distributed under the terms of Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

INTRODUCTION

Cervical infection with high-risk types of human papillomavirus (HPV) is the cause of most cervical cancers and their precursors.1 With the advent of HPV vaccinations and cervical cytology screening programs, cervical cancers are now considered preventable diseases.2,3 However, cervical malignancy is still a major public health issue in many developing or underdeveloped countries, and one of the most prevalent female malignancies worldwide.4

Low-grade squamous intraepithelial lesion (LSIL) development, a cytologic manifestation of HPV infection, is a distinct event in the natural history of HPV infection and cancer development.5 In most women with LSIL cytology, spontaneous regressions occur, but not at the same rate for all women.6–14 Risk factors for cervical precursor progression include smoking, long-term oral contraceptive use, multiparity, and lack of cytology-based screening.15–17 However, the biological behavior of LSIL cannot be completely explained by the conventional risk factors.

Inflammation has emerged as a potential mechanism of cancer development,18–20 including cervical cancer.21,22 Recently, a gene signature for low-grade inflammatory status, which is an intermediate state between tissue homeostasis and classic inflammation,23 was found in several cancers, suggesting that inflammatory status plays a role in carcinogenesis.24 In cervical cancer, only a few studies have explored the associations between systemic25–30 or cervical (local) inflammation31–34 and the risk of persistent HPV infection and/or cervical precursor progression, exhibiting a positive correlation.25–34 However, the evaluation of...
low-grade inflammation associated with LSIL regression, which is important in the onset of cervical cancer, is still lacking.

High-sensitivity C-reactive protein (hs-CRP) is one of the most frequently used systemic inflammatory biomarkers. Recent studies have suggested that it has a positive association with cancer.\(^4\) However, there have been no studies examining how hs-CRP affects cervical lesions. Herein, we investigated the biological behavior of LSIL in a large cohort of participants with incident cytologic LSIL, according to an inflammatory biomarker, hs-CRP.

**METHODS**

**Study population**

Kangbuk Samsung Health Study is a cohort study of Korean men and women who underwent a comprehensive annual or biennial health examination at Kangbuk Samsung Hospital Total Health-care Centers in Seoul and Suwon, South Korea.\(^3\) Over 80% of participants were employees of various companies and local governmental organizations or their spouses since the Industrial Safety and Health Law in South Korea requires annual or biennial health-screening exams, offered free of charge, for all employees. The remaining participants voluntarily purchased screening examinations at the health-screening center.

The present analysis includes a portion of the Kangbuk Samsung Health Study female participants aged 22 or older with cervical cytology examined between the years 2006 and 2015 \((n = 229,153)\).

We recruited incident LSIL participants who had one or more completely negative results and subsequent LSIL during the cervical screening test. We excluded participants who had any of the following conditions at baseline: completely negative results of cervical cytology during follow up \((n = 225,926)\); prevalent cervical abnormalities before the baseline visit \((n = 1,563)\); history of hysterectomy \((n = 21,225)\); a history of malignancy in cervix or uterus \((n = 1,845)\); or no follow-up cytology \((n = 3,569)\). Because some individuals met more than one exclusion criterion, the total number of subjects with incident LSIL, at least one follow-up cervical cytology, was 531. Among them, participants with missing hs-CRP \((n = 11)\) were excluded. For the final analysis, a total of 520 subjects with incident LSIL were recruited. This study was approved by the Institutional Review Board of Kangbuk Samsung Hospital (KBSMC 2017-11-014), which waived the requirement for informed consent due to the use of de-identified data obtained as part of routine health screening exams.

**Data collection**

Baseline and follow-up examinations were conducted at the clinics of Kangbuk Samsung Hospital Health Screening Center in Seoul and Suwon. Data on demographic characteristics, smoking status, alcohol consumption, physical activity, educational level, medical history, and medication use were collected using standardized, self-administered questionnaires, as previously described.\(^4\) Smoking status was categorized into never, former, or current smoker, and alcohol consumption into none, moderate \((<10 \text{ g/day})\), or high intake \((\geq 10 \text{ g/day})\). The weekly frequency of moderate or vigorous-intensity physical activity was also assessed. Height, weight, and sitting blood pressure (BP) were measured by trained nurses. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared and was categorized according to Asian-specific criteria.\(^2\) Hypertension was defined as systolic blood pressure \(\geq 140 \text{ mmHg}\), diastolic blood pressure \(\geq 90 \text{ mmHg}\), or current use of antihypertensive medications.

Serum levels of fasting glucose, total cholesterol, and hs-CRP were measured as previously described.\(^3\) Serum hs-CRP levels were analyzed via nephelometry using a BNII nephelometer (Dade Behring, Deerfield, IL, USA). Insulin resistance was assessed with the homeostatic model assessment of insulin resistance (HOMA-IR) equation: fasting blood insulin \((\mu \text{U/mL}) \times \text{fasting blood glucose (mmol/L)/22.5}'). Diabetes was defined as a fasting serum glucose \(\geq 126 \text{ mg/dL}\) or current use of anti-diabetic medications.

The cervical specimens were obtained using a DNA PAP Cervical Sampler and specimen transport medium (Qiagen). All specimens at baseline were tested with the HR Hybrid Capture 2 (HC2) assay (Qiagen, Gaithersburg, MD, USA) according to the manufacturer’s protocol. HC2 is a sandwich-capture molecular hybridization assay that uses chemiluminescent detection to provide a semi-quantitative result. Briefly, HPV DNA was denatured, and then the single-stranded HPV DNA was hybridized with a mixture of single-stranded, full-genomic-length RNA probes specific for 13 HR HPV genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Measurements below the relative-light-unit (RLU) cutoff of 1.0 were scored as negative. Positive and negative controls provided by the manufacturer were included in each run.

Regression in incident LSIL subjects was defined, based on the characteristics of our database that was from an annual or biennial screening exam, and the natural history of LSIL that is mostly determined within 1–2 years. The regression was defined as at least one consecutive negative result in follow-up cervical cytology. Persistence and progression, which were analyzed together as non-regression, were defined as ongoing abnormal cytologic results, including LSIL or above.

**Statistical analysis**

The characteristics of the study participants were explored according to hs-CRP quartiles \((\leq 0.2, 0.3–0.3, 0.4–0.6, \text{ or } \geq 0.7 \text{ mg/L})\). The primary endpoint was LSIL regression, defined as negative cytology at the second visit. Each participant was followed from their baseline exam until either LSIL regression or the last health exam conducted before December 31, 2015, whichever came first. The incidence rate was calculated as the number of incident cases divided by the number of person-years of follow-up. Since LSIL regressions would have occurred sometime between the two visits, but the precise time was unknown, a parametric proportional hazards model was used to account for this type of interval censoring (the `stpm` command in Stata).\(^3\) In these models, the baseline hazard function was parameterized with restricted cubic splines in log time with four degrees of freedom. The proportional hazards assumption was assessed by examining graphs of the estimated log \((-\log \text{[survival]}\))

The hazard ratio (HR) and 95% confidence interval (CI) were calculated for incident LSIL regression according to the serum hs-CRP levels. We then derived an inverse HR \((1/\text{HR})\) to label regression with HR that is directed towards the null \((<1.00)\), which improves understanding of the results and reduces the confusion. Data were adjusted for age, year of a screening exam, smoking status (never, past, current, or unknown), alcohol intake \((0, <10, \geq 10 \text{ g/day}, \text{ or unknown})\), marital status, HPV infection, history of diabetes, and education level (high school graduate or less, community college or university graduate, graduate school
Table 1. Baseline characteristics of study participants by hs-CRP level

| Characteristics          | Overall | Q1 (0.1–0.2 mg/L) | Q2 (0.3–0.3 mg/L) | Q3 (0.4–0.6 mg/L) | Q4 (0.7–1.5 mg/L) | P for trend |
|--------------------------|---------|-------------------|-------------------|-------------------|-------------------|------------|
| Number                   | 520     | 244               | 75                | 95                | 106               | <0.001     |
| Age, years\(^a\)         | 41.1 (5.3) | 40.3 (5.2)       | 41.3 (4.7)       | 42.4 (6.2)       | 41.4 (5.0)       | 0.013      |
| BMI, kg/m\(^2\)          | 21.6 (2.7) | 20.8 (2.1)       | 21.7 (2.2)       | 22.1 (2.5)       | 23.2 (3.4)       | <0.001     |
| Overweight, %\(^b\)      | 25.8    | 13.2              | 24.0              | 32.6              | 50.0              | <0.001     |
| Current smoker, %         | 2.9     | 0.5               | 3.2               | 6.4               | 5.7               | 0.006      |
| Alcohol intake, %\(^c\)  | 14.3    | 17.2              | 17.9              | 7.1               | 11.3              | 0.050      |
| Vigorous exercise, %\(^d\)| 19.0    | 19.8              | 19.4              | 20.7              | 15.5              | 0.487      |
| High education, %\(^e\)  | 66.1    | 65.9              | 67.9              | 57.4              | 73.3              | 0.635      |
| Married, %                | 93.3    | 94.1              | 92.5              | 93.4              | 92.3              | 0.659      |
| Menopause, %              | 8.5     | 7.4               | 6.2               | 12.3              | 9.3               | 0.356      |
| Hypertension, %           | 4.6     | 3.3               | 2.7               | 6.3               | 7.6               | 0.060      |
| Diabetes, %               | 1.9     | 0.4               | 4.0               | 2.1               | 3.8               | 0.051      |
| HPV infection, %          | 87.4    | 87.0              | 87.5              | 84.7              | 90.7              | 0.563      |
| Systolic BP, mm Hg\(^a\) | 104.3   | 103.4             | 101.3             | 105.1             | 108.0             | 0.001      |
| Glucose, mg/dL\(^a\)     | 92.1    | 90.5              | 92.3              | 92.3              | 95.2              | <0.001     |
| Total cholesterol, mg/dL\(^a\) | 186.2  | 185.6             | 187.3             | 184.9             | 188.1             | 0.604      |
| HOMA-IR\(^f\)            | 1.18    | 1.09              | 1.13              | 1.15              | 1.25              | 0.002      |

BMI, body mass index; BP, blood pressure; HOMA-IR, homeostasis model assessment of insulin resistance; HPV, human papillomavirus; hs-CRP, high sensitivity C-reactive protein.

Data are presented as \(^a\)mean (standard deviation), \(^b\)median (interquartile range), or percentage.

Table 2. Regression of LSIL by hs-CRP quartile

| hs-CRP quartiles | Person-years | Incident cases | Incidence Density (per 100 person-years) | Multivariate HR\(^e\) (95% CI) |
|------------------|--------------|----------------|------------------------------------------|-------------------------------|
| Q1 (0.1–0.2 mg/L) | 385.0        | 231            | 60.0                                     | 1.00 (reference)              |
| Q2 (0.3–0.3 mg/L) | 115.2        | 70             | 60.7                                     | 1.00 (0.76–1.32)              |
| Q3 (0.4–0.6 mg/L) | 141.9        | 87             | 61.3                                     | 1.05 (0.81–1.37)              |
| Q4 (0.7–1.5 mg/L) | 185.4        | 98             | 52.9                                     | 1.33 (1.04–1.69)              |

CI, confidence intervals; HR, hazard ratios; hs-CRP, high sensitivity C-reactive protein; LSIL, low-grade squamous intraepithelial lesion.

\(^a\)BMI ≥23 kg/m\(^2\); \(^b\)≥10 g of ethanol per day; \(^c\)≥3 time per week; \(^d\)≥College graduate.

or higher, or unknown). To determine linear trends of incidence, the number of quartiles was used as a continuous variable and tested for each model. To explore the shape of the dose-response relationship of hs-CRP levels with the LSIL regression, restricted cubic splines with knots were used at the 5th, 27.5th, 50th, 72.5th, and 95th percentiles of the hs-CRP distribution.

Additional subgroup analyses stratified by age (<50 vs ≥50 years), HPV infection (negative vs positive), smoking status (ever or current smoker vs never smoker), alcohol intake (<10 vs ≥10 g/day), BMI (<23 vs ≥23 kg/m\(^2\)), and HOMA-IR (<2.5 vs ≥2.5) were performed. Interactions between hs-CRP quartiles and subgroup characteristics were tested using likelihood ratio tests comparing models with versus without multiplicative interaction terms.

Statistical analyses were carried out using STATA version 15.0 (StataCorp LP, College Station, TX, USA). All P-values less than 0.05 were considered statistically significant.

RESULTS

Table 1 summarizes the baseline characteristics of the 520 participants of incident LSIL included in the present analysis according to quartiles of hs-CRP. The mean age of the study participants was 41.1 (standard deviation, 5.3) years. Women with higher hs-CRP were more likely to be older, obese, and current smokers. Blood pressure, glucose, and HOMA-IR were positively associated with the hs-CRP level.

During 827.5 person-years of follow-up, 486 participants showed spontaneous regression of LSIL. A negative association between high hs-CRP level and regression was found (Table 2). After adjusting for age, the year of a screening exam, smoking status, alcohol intake, marital status, education level, HPV infection, and history of diabetes, inverse HRs for LSIL regression comparing quartiles 2–4 vs quartile 1 of hs-CRP, were 1.00 (95% CI, 0.76–1.32), 1.05 (95% CI, 0.81–1.37), and 1.33 (95% CI, 1.04–1.69), respectively (P for trend = 0.03). In spline regression analyses, there was a nonlinear relationship between hs-CRP levels and the adjusted HRs for LSIL regression (Figure 1). In a sensitivity analysis, we examined the association between hs-CRP level and LSIL regression after excluding 3 women with hs-CRP values greater than 10 mg/L because such elevated values are likely to be caused by acute infection or underlying medication problems (eTable 1). The results did not qualitatively change.

The associations between the regression and serum hs-CRP levels were similar across participant subgroups (Table 2). There were no significant interactions according to age (<50 vs ≥50 years), HPV infection (negative vs positive), smoking status (ever
or current smoker vs never smoker), alcohol intake (<10 vs ≥10 g/day), BMI categories (<23 vs ≥23 kg/m²), or HOMA-IR (<2.5 vs ≥2.5).

**DISCUSSION**

To our knowledge, this is the first cohort study to examine the effects of host inflammation status on spontaneous regression of incident LSIL. We found a negative association between elevated hs-CRP and LSIL regression. These outcomes suggest that low-grade inflammation could affect the natural course of LSIL, which is biologically plausible considering that inflammation has a causal role in cervical carcinogenesis.

There were some reports on cervical precursor lesions or HPV infections associated with the perturbed host inflammatory responses. Prior cross-sectional analyses demonstrated that the cell-mediated immune response was decreased in the more severe cervical lesions, while overall immune activation was increased. Several longitudinal studies identified that the cell-mediated immune response could affect the regression of cervical lesions and/or HPV infection. In addition to systemic host inflammation, several studies assessed local immune responses, using inflammatory cells in the cervical specimens or inflammatory cytokines IL-6 and IL-8 in cervicovaginal lavages. They revealed that local immune responses increased with the severity of the cervical lesion and/or LSIL progression.

Previous studies assessed female participants with prevalent cervical lesions, whereas our study analyzed the women with the incident LSIL, which would be a more accurate reflection of the natural history of the disease. Moreover, some of these studies used cervical specimens obtained using colposcopic biopsy, which is a traumatic and invasive procedure that may elicit immune responses capable of affecting the natural course of cervical precursor lesions. Besides having small sample sizes (less than 100 LSIL cases), some are cross-sectional studies statistically limited by the temporal ambiguity between host immune response and the biological behavior of cervical lesions.

The exact mechanisms underlying low-grade inflammation and LSIL regression have not been fully elucidated. Persistent high-risk HPV infection is a prerequisite for the progression of high-grade lesions. Through degradation of the tumor suppressor proteins using viral oncoproteins E6 and E7, infected cervical epithelium could enter an uncontrolled cell cycle and a state of neoplastic transformation. These viral proteins are associated with the transition from chronic inflammation to cancer progression via increased activity of NF-κB. Subbaramaiah et al examined the link between HPV oncogenes and the inflammatory cascade and demonstrated overexpression of cyclooxygenase-2 pathways in HPV-infected cell lines. Altered immune response pathways and an imbalance of inflammatory cytokine profiles have been also noted as being responsible for the clearance of HPV infection, suggesting that chronic inflammation may be an important mechanism for host immune evasion and progression of the precursor lesions. Interestingly, long-term immune suppression induced by human immunodeficiency virus infection is associated with a high progression rate of premalignant cervical lesions, where CD4 cell counts are a possible risk factor for LSIL progression. Taken together, altered inflammatory status and persistent HPV infection could influence the natural course of cervical precursor lesions.

Smoking, a well-established risk factor for cervical cancer, leads to perturbations in the host immune response, and smokers may develop a state of persistent low-grade inflammation. Smoking as a risk factor for cervical cancers lends support to the role of low-grade inflammation in cervical carcinogenesis. In our study, we found a negative association between elevated hs-CRP levels and LSIL regression, even after adjusting for smoking. Thus, our study provides highly reliable evidence that low-grade inflammation could affect the biological behavior of LSIL.
Based on the well-known etiology of cervical cancer, screening tests for the entire population contributed to the dramatic decline in the incidence and mortality of cervical cancer.\textsuperscript{55} Our findings may help to better understand asymptomatic patients with low-grade lesions and further aid in the development of secondary prevention strategies. That is, hs-CRP, which is a feasible biomarker in practice, could be used to predict at-risk groups for malignant progression in LSIL patients.

Since obesity and/or metabolic syndrome have been reported to be associated with increased risk of HPV infection or its persistence,\textsuperscript{56,57} we have also evaluated whether or not the association between the hs-CRP level and LSIL regression differs based on the presence of overweight or insulin resistance. The associations between the regression and serum hs-CRP levels, however, did not differ by BMI categories ($<23$ vs $\geq23$ kg/m\textsuperscript{2}), or HOMA-IR ($<2.5$ vs $\geq2.5$). And the lack of association between hs-CRP and LSIL were observed in each subgroup, which can be explained by the small number of subgroups, which may be insufficient to establish a relationship and lead to imprecise estimates.

There are several strengths of the present study. Systemic follow-up data from a relatively large sample size allowed us to establish temporal relationships between serum hs-CRP levels and LSIL regression. Besides, we adjusted for several important potential confounders, including smoking and HPV infection, which could affect the association between hs-CRP and LSIL regression. Finally, our study population is comprised of incident LSIL women who underwent a cervical cytology test for a health screening program, thus our results may reflect the natural course of LSIL regression in a low-risk general population.

Our study has a few limitations to consider. First, a single measurement of hs-CRP may not represent an individual’s inflammatory status during persistent LSIL, since levels can be affected by diurnal cycles or stress-induced variations. Second, these results do not exclude the possibility that hs-CRP elevation is the consequence of undetected, long-latency precancerous lesions. Third, the participants in our study consisted of young and middle-aged Korean women with relatively high socio-economic status and educational level, so the generalizability of our findings may be limited when considering other age groups or populations with a higher prevalence of comorbidities, such as common genital infections or HIV. Last, in our analysis we do not include an important variable, sexual activity, which affects the biological behavior of LSIL. That variable should depend on the subjects’ survey, so there would be a high possibility of measurement errors, such as underestimation, considering the conservative sentiment of Korean society, if sexual activity were applied in the analysis.

In conclusion, elevated hs-CRP levels show a negative association with LSIL regression, suggesting that low-grade host systemic inflammation could affect the biological behavior of LSIL. Further studies on the regression of LSIL in relation to host systemic inflammation may provide insights into the mechanisms that contribute to the development of the malignant phenotype and may suggest novel approaches to the prevention of cervical neoplasia.

ACKNOWLEDGMENTS

Funding: This research was supported by National Research Foundation of Korea (NRF-2019R1G1A1004267).

Conflicts of interest: None declared.

Author contributions: S Ryu, and JH Sohn, substantially contributed to the conceptualization, supervision and, writing. S Ahn contributed to writing the initial draft. GJ Kim, SI Do, K Kim, H Lee, IG Do, DH Kim, and SW Chae contributed to the resources. All authors discussed the results and commented on the manuscript.

**APPENDIX A. SUPPLEMENTARY DATA**

Supplementary data related to this article can be found at https://doi.org/10.21888/jea.JE20200142.

**REFERENCES**

1. Bosch FX, Lorinzz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. *J Clin Pathol*. 2002;55:244–265.

2. Gustafsson L, Pontén J, Bergström R, Adami HO. International incidence rates of invasive cervical cancer before cytological screening. *Int J Cancer*. 1997;71:159–165.

3. Gustafsson L, Pontén J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. *Cancer Causes Control*. 1997;8:755–763.

4. Small W Jr, Bacon MA, Bajaj A, et al. Cervical cancer: a global health crisis. *Cancer*. 2017;123:2404–2412.

5. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. *JAMA*. 2001;285:2995–3002.

6. Nash JD, Burke TW, Hoskins WJ. Biologic course of cervical human papillomavirus infection. *Obstet Gynecol*. 1987;69:160–162.

7. Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dysplasia during long-term follow-up. *Obstet Gynecol*. 1986;67:665–669.

8. Sryjåsen K, Kataja V, Yliselos M, Chang F, Sryjåsen S, Saarikoski S. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. *Obstet Gynecol*. 1992;79:675–682.

9. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. *Am J Obstet Gynecol*. 2007;197:356.e1–356.e16.

10. Wright TC Jr, Cox JT, Massad LS, Carlson J, Twigg LS, Wilkinson EJ. American Society for Colposcopy and Cervical Pathology. 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. *Am J Obstet Gynecol*. 2003;189(1):295–304.

11. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin number 66, September 2005. Management of abnormal cervical cytology and histology. *Obstet Gynecol*. 2005;106(3):645–664.

12. Cox JT, Schiffman M, Solomon D; ASCUS-LSIL Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. *Am J Obstet Gynecol*. 2003;188(6):1406–1412.

13. Ostör AG. Natural history of cervical intraepithelial neoplasia: a critical review. *Int J Gynecol Pathol*. 1993;12(2):186–192.

14. Schiffman M, Khan MJ, Solomon D, et al; PEG Group; ALTS Group. A study of the impact of adding HPV types to cervical cancer screening and triage tests. *J Natl Cancer Inst*. 2005;97(2):147–150.

15. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. *Lancet*. 2007;370(9599):1609–1621.

16. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, et al. Carcinoma of the cervix and tobacco smoking: collaborative
research and individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118(6):1481–1495.

17. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer. 2006;119(5):1108–1124.

18. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:885–899.

19. Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A. Pathways connecting inflammation and cancer. Curr Opin Genet Dev. 2008;18:3–10.

20. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444.

21. Boccardo E, Lepique AP, Villa LL. The role of inflammation in HPV carcinogenesis. Carcinogenesis. 2010;31:1905–1912.

22. Parida S, Mandal M. Inflammation induced by human papillomavirus in cervical cancer and its implication in prevention. Eur J Cancer Prev. 2014;23:432–448.

23. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428–435.

24. Aran D, Lasy A, Zinger A, et al. Widespread parainflammation in human cancer. Genome Biol. 2016;17:145.

25. Kemp TJ, Hildesheim A, Garcia-Piñeres AJ, et al. Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1954–1959.

26. Sharma A, Rajappa M, Saxena A, Sharma M. Cytokine profile in Indian women with cervical intraepithelial neoplasia and cervical cervix. Int J Gynecol Cancer. 2007;17:879–885.

27. Kadish AS, Timmins P, Wang Y, et al. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev. 2002;11:483–488.

28. Hildesheim A, Schiffman MH, Tsukui T, et al. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease. Cancer Epidemiol Biomarkers Prev. 1997;6:807–813.

29. Garcia-Piñeres AJ, Hildesheim A, Herrero R, et al. Persistent human papillomavirus infection is associated with a generalized increase in immune responsiveness in older women. Cancer Res. 2006;66(22):11070–11076.

30. Trimble CL, Piantadosi S, Griffitt P, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res. 2005;11:4717–4723.

31. Hammes LS, Tekmal RR, Naud P, et al. Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression—clinico-pathological correlation. Gynecol Oncol. 2007;105:157–165.

32. Castle PE, Hillier SL, Rabe LK, et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev. 2001;10:1021–1027.

33. Davidson B, Goldberg I, Kopolovic J. Inflammatory response in cervical intraepithelial neoplasia and squamous cell carcinoma of the uterine cervix. Pathol Res Pract. 1997;193:491–495.

34. Tjong MY, van der Vange N, ten Kate FJ, et al. Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecol Oncol. 1999;73:285–291.

35. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res. 2006;66:2483–2487.

36. Chiu HM, Lin JT, Chen TH, et al. Elevation of C-reactive protein level is associated with synchronous and advanced colorectal neoplasm in men. Am J Gastroenterol. 2008;103:2317–2325.

37. Sasazuki S, Inoue M, Sawada N, et al; Japan Public Health Center-Based Prospective Study Group. Plasma levels of C-reactive protein and serum amyloid A and gastric cancer in a nested case-control study: Japan Public Health Center-based prospective study. Carcinogenesis. 2010;31(4):712–718.

38. Lee S, Choe JW, Kim HJ, Sung J. High-sensitivity C-reactive protein and cancer. J Epidemiol. 2011;21:161–168.

39. Ryu S, Chang Y, Choi Y, et al. Age at menarche and non-alcoholic fatty liver disease. J Hepatol. 2015;62:1164–1170.

40. Chang Y, Kim BK, Yun KE, et al. Metabolically-healthy obesity and coronary artery calcification. J Am Coll Cardiol. 2014;63:2679–2686.

41. Kim S, Chang Y, Yun KE, et al. Development of nephro lithiasis in asymptomatic hyperuricemia: a cohort study. Am J Kidney Dis. 2017;70:173–181.

42. World Health Organization, Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia; 2000.

43. Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21:2175–2197.

44. Newton RB. Comparing the predictive powers of survival models using Harrell’s C or Somers’ D. Stat J. 2010;10:339–358.

45. Pearson TA, Mensah GA, Alexander RW, et al; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499–511.

46. Groves U, Coleman N. Pathogenesis of human papillomavirus-associated mucosal disease. J Pathol. 2015;235:527–538.

47. Senba M, Mori N. Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection. Oncol Rev. 2012;6:417.

48. Senba M, Buziba N, Mori N, et al. Human papillomavirus infection induces NF-kappaB activation in cervical cancer: a comparison with periure cancer. Oncol Lett. 2011;2:65–68.

49. James MA, Lee HJ, Klingelhutz AJ. Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J Virol. 2006;80:5301–5307.

50. Subbaramaiah K, Dunnebacke AJ. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/activator exchange. Cancer Res. 2007;67:3976–3985.

51. Sahebali S, Van den Eynden G, Murta EF, et al. Stromal issues in cervical cancer: a review of the role and function of basement membrane, stroma, immune response and angiogenesis in cervical cancer development. Eur J Cancer Prev. 2010;19:204–215.

52. Chen Z, Ding J, Pang N, et al. The Th17/Treg balance and the expression of related cytokines in Uygur cervical cancer patients. Diagn Pathol. 2013;8:61.

53. Omar T, Schwartz S, Hanrahane C, et al. Progression and regression of premalignant cervical lesions in HIV-infected women from Sofeto: a prospective cohort. AIDS. 2011;25:87–94.

54. Shiels MS, Katki HA, Freedman ND, et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst. 2014;106(11):dju294.

55. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

56. Molokwu JC, Penaranda E, Lopez DS, Dwivedi A, Dodoo C, Molokwu JC. Progression and regression of premalignant cervical lesions in HIV-infected women from Sofeto: a prospective cohort. AIDS. 2011;25:87–94.

57. Shiel MS, Katki HA, Freedman ND, et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst. 2014;106(11):dju294.